from First Patient Cohort of Phase 2a Trial of AZP-3601 for the Treatment of Hypoparathyroidism
Amolyt Pharma, a global company specialized in developing therapeutic peptides for rare endocrine and related diseases, today announced positive results from the first cohort of its clinical proof of concept trial of AZP-3601, which the company is developing as a potential treatment for hypoparathyroidism. The data demonstrate that AZP-3601 was well-tolerated and daily administration to patients enabled discontinuation of the standard of care while mean serum calcium was maintained within the target range. Detailed data from cohort 1 will be presented at an upcoming medical conference later this year and full data is expected in fall 2022.